论文部分内容阅读
目的观察卡维地洛对慢性充血性心力衰竭(心衰)患者脑钠素(BNP)浓度的影响及其同心衰预后的关系。方法68例心衰患者随机分为对照组(常规治疗)32例和治疗组(加用卡维地洛)36例。测定两组患者治疗前、治疗2周后BNP浓度及心功能,观察卡维地洛对BNP浓度的影响;以6个月内再住院或死亡作为观察终点,评价卡维地洛对心衰预后的影响。结果两组治疗后均有BNP浓度下降,治疗组BNP浓度下降更明显(P<0.05);治疗组4例发生终点事件,发生率11.1%,对照组13例发生终点事件,发生率40.6%,对照组终点事件发生率高(P<0.01)。结论卡维地洛可以改善心衰患者预后,BNP浓度可以预测心衰患者预后。
Objective To observe the effect of carvedilol on the concentration of brain natriuretic peptide (BNP) in patients with chronic congestive heart failure (CHF) and its relationship with the congestive heart failure. Methods 68 patients with heart failure were randomly divided into control group (conventional treatment) 32 cases and treatment group (plus carvedilol) 36 cases. The levels of BNP and heart function in two groups before and after treatment were measured to observe the effect of carvedilol on the concentration of BNP. The hospitalization or death within 6 months was used as the end point to evaluate the effect of carvedilol on the prognosis of heart failure Impact. Results The BNP levels in both groups decreased after treatment, and the BNP levels in the treatment group decreased more significantly (P <0.05). In the treatment group, 4 patients had an end point event with a rate of 11.1%, while the control group had an end point event rate of 40.6% The incidence of end points in the control group was high (P <0.01). Conclusion Carvedilol can improve the prognosis of patients with heart failure, BNP concentration can predict the prognosis of patients with heart failure.